Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China

Abstract

Background In December 2019, coronavirus disease 2019 (COVID-19) outbreak was reported from Wuhan, China. Information on the clinical course and prognosis of COVID-19 was not thoroughly described. We described the clinical courses and prognosis in COVID-19 patients. Methods Retrospective case series of COVID-19 patients from Zhongnan Hospital of Wuhan University in Wuhan and Xishui Hospital, Hubei Province, China, up to February 10, 2020. Epidemiological, demographic, and clinical data were collected. The clinical course of survivors and non-survivors were compared. Risk factors for death were analyzed. Results A total of 107 discharged patients with COVID-19 were enrolled. The clinical course of COVID-19 presented as a tri-phasic pattern. Week 1 after illness onset was characterized by fever, cough, dyspnea, lymphopenia, and radiological multi-lobar pulmonary infiltrates. In severe cases, thrombocytopenia, acute kidney injury, acute myocardial injury, and adult respiratory distress syndrome were observed. During week 2, in mild cases, fever, cough, and systemic symptoms began to resolve and platelet count rose to normal range, but lymphopenia persisted. In severe cases, leukocytosis, neutrophilia, and deteriorating multi-organ dysfunction were dominant. By week 3, mild cases had clinically resolved except for lymphopenia. However, severe cases showed persistent lymphopenia, severe acute respiratory dyspnea syndrome, refractory shock, anuric acute kidney injury, coagulopathy, thrombocytopenia, and death. Older age and male sex were independent risk factors for poor outcome of the illness. Conclusions A period of 7–13 days after illness onset is the critical stage in the COVID-19 course. Age and male gender were independent risk factors for death of COVID-19.

Cited by papers we hold 12

• Dynamics of laboratory indicators against the background of antibacterial therapy regimens that included fluoroquinolones in the treatment of critically ill COVID-19 patients depending on their age and doses of hormonal drugs · 2021
  Not checked
• Gender-based differences in COVID-19 · 2021
  Not checked
• Biomarkers in COVID-19: An Up-To-Date Review · 2021
  No notice
• Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury · 2021
  No notice
• Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis · 2021
  No notice
• Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19 · 2021
  No notice
• Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence · 2021
  No notice
• The Involvement of Chronic Kidney Disease and Acute Kidney Injury in Disease Severity and Mortality in Patients with COVID-19: A Meta-Analysis · 2020
  Not checked
• Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review · 2020
  Corrected
• Factors associated with disease severity and mortality among patients with COVID-19: A systematic review and meta-analysis · 2020
  No notice
• The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis, and Meta-Regression · 2020
  No notice
• Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2 · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.